413 related articles for article (PubMed ID: 22753589)
1. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
[TBL] [Abstract][Full Text] [Related]
2. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840
[TBL] [Abstract][Full Text] [Related]
4. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
[TBL] [Abstract][Full Text] [Related]
5. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S
Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
[TBL] [Abstract][Full Text] [Related]
9. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.
Morikawa T; Kuchiba A; Liao X; Imamura Y; Yamauchi M; Qian ZR; Nishihara R; Sato K; Meyerhardt JA; Fuchs CS; Ogino S
Int J Cancer; 2012 Sep; 131(5):1169-78. PubMed ID: 22038927
[TBL] [Abstract][Full Text] [Related]
10. Association between molecular subtypes of colorectal cancer and patient survival.
Phipps AI; Limburg PJ; Baron JA; Burnett-Hartman AN; Weisenberger DJ; Laird PW; Sinicrope FA; Rosty C; Buchanan DD; Potter JD; Newcomb PA
Gastroenterology; 2015 Jan; 148(1):77-87.e2. PubMed ID: 25280443
[TBL] [Abstract][Full Text] [Related]
11. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
Firestein R; Shima K; Nosho K; Irahara N; Baba Y; Bojarski E; Giovannucci EL; Hahn WC; Fuchs CS; Ogino S
Int J Cancer; 2010 Jun; 126(12):2863-73. PubMed ID: 19790197
[TBL] [Abstract][Full Text] [Related]
12. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
15. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.
Li T; Liao X; Lochhead P; Morikawa T; Yamauchi M; Nishihara R; Inamura K; Kim SA; Mima K; Sukawa Y; Kuchiba A; Imamura Y; Baba Y; Shima K; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S; Qian ZR
Ann Surg Oncol; 2014 Dec; 21(13):4164-73. PubMed ID: 25023548
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
[TBL] [Abstract][Full Text] [Related]
17. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.
Yamauchi M; Morikawa T; Kuchiba A; Imamura Y; Qian ZR; Nishihara R; Liao X; Waldron L; Hoshida Y; Huttenhower C; Chan AT; Giovannucci E; Fuchs C; Ogino S
Gut; 2012 Jun; 61(6):847-54. PubMed ID: 22427238
[TBL] [Abstract][Full Text] [Related]
18. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS
J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]